- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01403233
Bioavailability of Two Doses of cogniVida™ With One Dose of Rebaudioside A in Healthy Male Subjects (StevReb-PK)
An Open-label, Sequential Supplementation Study Comparing the Bioavailability of Two Doses of cogniVida™ With One Dose of Rebaudioside A in Healthy Male Subjects
The purpose of the study is to examine the bioavailability of cogniVida™ in 10 healthy male subjects after consumption of two different doses of cogniVida™ (50 mg and 100 mg) and to compare the plasma values with values obtained in subjects receiving rebaudioside A (303.68 mg). In addition, also safety and tolerability parameters 24 hours after ingestion of the study compounds will be determined.
cogniVida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The investigators do not claim that this supplement is meant to treat any ailment.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Ontario
-
London, Ontario, Canada, N6A 5R8
- KGK Synergize Inc
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Sex: Male, age 30 - 50 years
- Subject is willing to maintain his or her habitual diet and physical activity patterns throughout the study period.
- Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history and routine laboratory test results
- Subject has a body mass index (BMI) of ≥20.00 and <28.00 kg/m2 at screening.
- Subject is willing to refrain from consuming drinks containing grapefruit 7 days prior to test days.
- Subject is willing to refrain from consuming caffeine, caffeine-containing products and alcoholic drinks 24 h prior to test days and until the end of each assessment period.
- Subject is willing to refrain from vigorous physical activity 12 h prior to test days.
- Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
Exclusion Criteria:
- Subject has a positive drug screening of amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methamphetamines, methadone, 3,4-methylenedioxymethamphetamine, opiates or tricyclic antidepressants at screening.
- Subjects has a positive blood alcohol and breath carbon monoxide test at screening.
- Subject has abnormal laboratory test results of clinical significance, including, but not limited to: Epidermal-Growth-Factor-Receptor (eGFR) <60mL/min/1.73m2, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5X the upper limit of normal at screening.
- Subject has donated more than 300 mL of blood or has lost a significant amount of blood during the three months prior to screening.
- Anemia of any etiology defined as hemoglobin < 140g/L for males and < 123g/L for female
- Subject has uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) as defined by the average blood pressure measured at screening.
- Subject has a history or presence of cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorders.
- Subject has a history, in the judgment of the Investigator, of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
- Subject has a history or presence of cancer in the prior five years, except for non-melanoma skin cancer.
- Excessive habitual caffeine consumption (>300 mg caffeine/d or ≥ 3 cups of caffeinated coffee/d), following screening and throughout the study period.
- Use of antibiotics or signs of active systemic infection. Treatment visits will be rescheduled to allow the subject to wash off of the antibiotic for at least one month prior to any test visit.
- Use of dietary supplements containing any of the following: ginkgo biloba, St. John's wort, ginseng, gotu kola (Indian pennywort); daily doses of vitamin E (≥30 mg/d) or folic acid (≥400 ug/d); thiamine, riboflavin, and/or pyridoxine (≥2 mg/d); and eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)or a combination of EPA + DHA (≥500 mg/d) within 2 weeks prior to screening.
- Consumption of stevia extract (reb A / steviosides) sweetened products/drinks or stevia leaves within one month of the study.
- Subject has had exposure to any non-registered drug product within 30 days prior to the screening visit.
- Recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
- Subject has a known allergy or sensitivity to study product or any ingredients of the study product or meals provided.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: cogniVida™ 50 mg/day
|
2 capsules 25 mg (total 50 mg) cogniVida™ once a day
|
Experimenteel: cogniVida™ 100 mg/dag
|
4 capsules 25 mg (total 100 mg) cogniVida™ once a day
|
Actieve vergelijker: Rebaudioside-A 303.7 mg/day
|
4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Plasma Area under the Curve (AUC) (0-72 hours) being produced after cogniVida™ (50 and 100 mg) and rebaudioside A (303.68 mg) consumption
Tijdsspanne: 0 - 72 hours
|
Blood sampling timepoints: cogniVida: 0 min, 15min, 30min, 45min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48, and 72h after dosing. RebA: 0 min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36, 48, and 72h after dosing |
0 - 72 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Time to plasma peak (Tmax) being produced after cogniVida™ (50 and 100 mg) and rebaudioside A (303.68 mg) consumption
Tijdsspanne: 0 - 72 hours
|
Blood sampling timepoints: cogniVida: 0 min, 15min, 30min, 45min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48, and 72h after dosing. RebA: 0 min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36, 48, and 72h after dosing |
0 - 72 hours
|
Plasma Peak Concentration (Cmax) being produced after cogniVida™ (50 and 100 mg) and rebaudioside A (303.68 mg) consumption
Tijdsspanne: 0 - 72 hours
|
Blood sampling timepoints: cogniVida: 0 min, 15min, 30min, 45min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48, and 72h after dosing. RebA: 0 min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36, 48, and 72h after dosing |
0 - 72 hours
|
Time to reach half of peak concentration in plasma T1/2 being produced after cogniVida™ (50 and 100 mg) and rebaudioside A (303.68 mg) consumption
Tijdsspanne: 0 - 72 hours
|
Blood sampling timepoints: cogniVida: 0 min, 15min, 30min, 45min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48, and 72h after dosing. RebA: 0 min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36, 48, and 72h after dosing |
0 - 72 hours
|
Vital signs
Tijdsspanne: 24 hours after each supplementation
|
Vital signs as safety parameters being measured 24 h after each supplementation.
|
24 hours after each supplementation
|
White blood cell (WBC) count (Routine Haematology)
Tijdsspanne: 24 hours after each supplementation
|
White blood cells will be counted as a routine haematology parameter to assess safety 24 h after each supplementation.
|
24 hours after each supplementation
|
Hemoglobin (Routine Haematology)
Tijdsspanne: 24 hours after each supplementation
|
Hemoglobin will be measured as a routine haematology parameter to assess safety 24 h after each supplementation.
|
24 hours after each supplementation
|
Blood urea nitrogen (BUN) (Clinical Chemistry)
Tijdsspanne: 24 hours after each supplementation
|
Blood urea nitrogen will be measured as a routine clinical chemistry parameter to assess safety 24 h after each supplementation.
|
24 hours after each supplementation
|
Cystatin-C (Clinical Chemistry)
Tijdsspanne: 24 hours after each supplementation
|
Cystatin-C will be measured as a routine clinical chemistry parameter to assess safety 24 h after each supplementation.
|
24 hours after each supplementation
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 2010-06-01-STEV
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezond
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
Klinische onderzoeken op cogniVida 50mg/day
-
DSM Nutritional Products, Inc.Voltooid
-
University of Nevada, Las VegasWervingTBI (Traumatisch Hersenletsel) | Oefening | Hersenschudding | Revalidatie | Lopen | Cognitie | Klinische proef | Psychosociaal functioneren | microRNA | Mobiele applicatie | Speeksel | Visie, oculairVerenigde Staten
-
Karolinska InstitutetRegion Stockholm; ForteActief, niet wervendHartinfarct | Niet-overdraagbare ziektenZweden
-
Massachusetts General HospitalAmerican Cancer Society, Inc.Beëindigd
-
Unilever R&DWorld Dental Federation (FDI)VoltooidTandplak | Gedrag | Gedrag, gezondheidIndonesië, Niger
-
Johnson & Johnson Vision Care, Inc.VoltooidGezichtsscherpteVerenigde Staten
-
Galapagos NVVoltooid
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Onbekend
-
University of Wisconsin, MadisonUrban League of Greater Madison; African American Council of Churches Madison; Second... en andere medewerkersVoltooidDepressie | Zelfmanagement | BewustzijnVerenigde Staten
-
SynAct Pharma ApsVoltooidReumatoïde artritisDenemarken, Noorwegen